Here are five things to know:
1. Study authors performed a retrospective radiological review of all femoral fractures in Quebec City, Canada, between Jan. 1, 2006, and March 31, 2015, using the American Society of Bone and Mineral Research Task Force’s criteria to identify atypical fractures.
2. Among patients who sustained periprosthetic femoral fractures, 8.3 percent had APFFs.
3. Study authors observed a strong association between bisphosphonate use and elevated risk of APFFs among alendronate users compared to risedronate users.
4. Risk factors for APFFs included transverse fractures, periosteal thickening of the lateral cortex at the fracture, unicortical fracture and prodromal symptoms.
5. The type of implant, its positioning and the femoral geometry were not risk factors for APFFs as compared to PFFs.
More articles on devices:
Spinal implants market to exceed $19.5B by 2024 — 8 leading market players
Stryker, NuVasive, DePuy Synthes & more: 12 device company notes
What to expect from RTI Surgical in the future: 4Qs with CEO Camille Farhat
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
